Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is presenting in vivo preclinical results at the Society for Neuroscience's annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson's diseases.
The effect of two chemically distinct σ-2 receptor modulators in a mouse model of Alzheimer's disease on gene and protein expression are presented. Data shed light on the molecular mechanisms and build upon previous studies in this same mouse model where Cognition's lead candidate, CT1812 was previously shown to decrease binding of Aβ oligomers to neuronal synapses and ameliorate cognitive deficits.
Separately, work supported by a Michael J. Fox Foundation grant award is presented defining the impact of σ-2 receptor modulators on gene and protein expression. In two different rat models of Parkinson's disease, the same two σ-2 receptor modulators are shown to effect pathways associated with Parkinson's disease, including cell survival, metabolism, autophagy, and protein/lipid transport.
Posted In: CGTX